Phase I/II trial of E6-TCR as a monotherapy and in combination with a checkpoint inhibitor in HPV-16 associated solid tumors

Trial Profile

Phase I/II trial of E6-TCR as a monotherapy and in combination with a checkpoint inhibitor in HPV-16 associated solid tumors

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs E6 TCR (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Penile cancer; Vulvovaginal cancer
  • Focus Adverse reactions
  • Sponsors Kite Pharma
  • Most Recent Events

    • 06 Oct 2015 New trial record
    • 01 Oct 2015 According to a media release, Kite Pharma expects to file an IND for this company-sponsored trial in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top